Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 16/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3229889 | 1.00 | SLC6A2 (0.50) | SLC6A2SLC6A4CYP2D6MEN1CYP1A2 | |
| SCHEMBL3223128 | 0.86 | FGFR1 (0.35) | SLC6A2SLC6A4CYP2D6KMT2ASLC6A3 | |
| SCHEMBL13678887 | 0.86 | SLC6A2 (0.36) | SLC6A2SLC6A4CYP2D6SLC6A3HRH1 | |
| SCHEMBL3223123 | 0.86 | FGFR1 (0.35) | SLC6A2SLC6A4CYP2D6KMT2ASLC6A3 | |
| SCHEMBL3233446 | 0.85 | SLC6A2 (0.51) | SLC6A2SLC6A4CYP2D6MEN1CYP1A2 | |
| SCHEMBL2074378 | 0.80 | SLC6A2 (0.63) | SLC6A2SLC6A4CYP2D6MEN1CYP1A2 | |
| SCHEMBL3218825 | 0.77 | SLC6A2 (0.66) | SLC6A2SLC6A4HTR2AHRH1 | |
| SCHEMBL3225255 | 0.77 | SLC6A2 (0.66) | SLC6A2SLC6A4HTR2AHRH1 | |
| SCHEMBL2071536 | 0.75 | SLC6A2 (0.63) | SLC6A2SLC6A4CYP2D6MEN1CYP1A2 | |
| SCHEMBL2074609 | 0.75 | SLC6A2 (0.56) | SLC6A2SLC6A4CYP2D6MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957488-B1 | 3-AMINO-2-ARYLPROPYL AZAINDOLES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2009-09-09 | — | — | EP | claimed |
| EP-1957488-A1 | 3-AMINO-2-ARYLPROPYL AZAINDOLES AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-20 | — | — | EP | claimed |
| WO-2007062998-A1 | 3-AMINO-2-ARYLPROPYL AZAINDOLES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | claimed |
| US-20100056499-A1 | 3-AMINO-1-ARYLPROPYL AZAINDOLES AND USES THEREOF | GREENHOUSE ROBERT | 2010-03-04 | — | — | US | disclosed |
| US-20100056499-A1 | 3-AMINO-1-ARYLPROPYL AZAINDOLES AND USES THEREOF | GREENHOUSE ROBERT | 2010-03-04 | — | — | US | disclosed |
| US-20100056499-A1 | 3-AMINO-1-ARYLPROPYL AZAINDOLES AND USES THEREOF | GREENHOUSE ROBERT | 2010-03-04 | — | — | US | disclosed |
| US-7638517-B2 | 3-Amino-1-arylpropyl azaindoles and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638517-B2 | 3-Amino-1-arylpropyl azaindoles and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-12-29 | — | — | US | disclosed |
| EP-1957488-B1 | 3-AMINO-2-ARYLPROPYL AZAINDOLES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2009-09-09 | — | — | EP | disclosed |
| WO-2007062998-A1 | 3-AMINO-2-ARYLPROPYL AZAINDOLES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070123535-A1 | 3-Amino-1-arylpropyl azaindoles and uses thereof | ROCHE PALO ALTO LLC | 2007-05-31 | — | — | US | disclosed |
| US-20070123535-A1 | 3-Amino-1-arylpropyl azaindoles and uses thereof | ROCHE PALO ALTO LLC | 2007-05-31 | — | — | US | disclosed |
| US-20070123535-A1 | 3-Amino-1-arylpropyl azaindoles and uses thereof | ROCHE PALO ALTO LLC | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123535-A1 | 3-Amino-1-arylpropyl azaindoles and uses thereof | CNKSR1, AR, CYP3A43 | SLC6A2 2283/4885SLC6A4 2174/4885CYP2D6 19/4885 |
| US-20100056499-A1 | 3-AMINO-1-ARYLPROPYL AZAINDOLES AND USES THEREOF | CNKSR1, AR, CYP3A43 | SLC6A2 2283/4885SLC6A4 2174/4885CYP2D6 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.